Breakthrough mouse model of celiac disease could lead to new treatments

UChicago researchers develops first accurate model that reflects gluten’s effect on humans

University of Chicago researchers have developed the first truly accurate mouse model of celiac disease—a scientific breakthrough more than 20 years in the making. 

Their new study, published this week in Nature, describes their development of a model organism with the same genetic and immune system characteristics as humans who develop celiac after eating gluten. The research provides a vital tool for developing and testing new treatments for the disease.

“Based on our understanding of the human disease, we were able to retro-engineer a mouse model of celiac disease,” said Prof. Bana Jabri, the study’s senior author and a leading researcher of celiac disease and autoimmune disorders. “It’s the first model where the mouse develops damage to the small intestine just by eating gluten, which can later reverse itself on a gluten-free diet.”

Celiac disease is an autoimmune disorder that affects an estimated 1% of people worldwide. It causes gastrointestinal symptoms and damage to the lining of the small intestine when someone eats gluten, a protein found in grains such as wheat, barley and rye.

There is no cure, and the only effective treatment is a gluten-free diet, which can be difficult to maintain. Even while maintaining a strict gluten-free diet, 40% of celiac disease patients still show signs of inflammation and villous atrophy, or damage to the villi, the small, finger-like protrusions in the small intestine that help absorb nutrients. Therefore, treatments that can reverse or prevent the disease are greatly needed to improve quality of life for people with celiac.

A complex interplay of contributing factors

Scientists do not know the exact cause of celiac disease, but researchers have identified several genetic, immune system and environmental components that work together to trigger the disease. People with celiac have one of two genetic variants, HLA-DQ2 and HLA-DQ8, that are part of a group of genes that help the immune system recognize foreign antigens and mount an immune response. However, possessing one these variants is not sufficient to develop the disease alone.

Based on studies in celiac disease patients, Jabri and her colleagues have proposed that signs of tissue distress associated with high levels of an inflammatory protein called IL-15 in the lining of the small intestine were required to cause villous atrophy, the hallmark of the disease.

Certain environmental factors may come into play as well. In 2017, for example, Jabri and her team discovered that a common and relatively harmless virus can cause changes to the immune system that set the stage for celiac. All of these factors work together to trigger an autoimmune response when someone ingests gluten that causes villous atrophy.

All the pieces fall into place

For decades, researchers have attempted to develop a mouse model for celiac that reflects these conditions. However, none of these models resulted in mice with one of the HLA gene variants that also developed villous atrophy in response to gluten.  

“In celiac, the main feature of disease is tissue destruction of the small intestinal lining,” said Valerie Abadie, a research assistant professor at UChicago and lead author of the study. “This new HLA-DQ8 mouse model is unique because it’s the only one that actually develops villous atrophy when the animal does eat gluten. In addition, once the mice are placed on a gluten-free diet, their small intestine can recover and heal, just as in humans with celiac disease.”

Jabri, the director of research at the University of Chicago Medicine Celiac Disease Center, said that all of these elements must be present in a research model to truly represent the conditions that cause disease in humans.

The new mouse model provides a vital tool for developing new treatments to reverse celiac once it has developed—or prevent it from developing in people at risk for the disease. Researchers will be able to identify new targets for drugs and then test them in a model that faithfully represents the condition in humans.

“This wouldn’t be possible without first conducting human studies to understand the nature of the disease,” Jabri said. “Now, using the mouse model, we can interrogate more and apply what we learned back into the human system. The integration of those two approaches is very important.”

Additional authors include Sangman M. Kim from the University of San Francisco; Thomas Lejeune, Mohamed Fahmy, Anne Dumaine, Vania Yotova, and Jean-Christophe Grenier from the University of Montreal and Sainte-Justine Hospital Research Centre; Brad A. Palanski and Chaitan Khosla from Stanford University; Eric V. Marietta, Irina Horwath and Joseph A. Murray from Mayo Clinic; and Jordan D. Ernest, Olivier Tastet, Jordan Voisine, Valentina Discepolo, Cezary Ciszewski, Romain Bouziat, Kaushik Panigrahi, Matthew A. Zurenski, Ian Lawrence and Luis B. Barreiro from the University of Chicago.

Citation: “IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease,” Feb. 12, 2020

Funding: The National Institutes of Health, the UChicago Digestive Diseases Research Core Center, F. Oliver Nicklin via the First Analysis Institute of Integrative Studies, the Regenstein Foundation, the SickKids Foundation, the Canadian Celiac Association, the Wallonie-Bruxelles International-World Excellence award, Fonds de Recherche du Québec, and the Carlino Fellowship for Celiac Disease Research at the UChicago Celiac Disease Center.

— Article was first published on the UChicago Medicine website.